Royalty PharmavsThermo Fisher Scientific

RPRX and TMO stock compared: price, dividend, valuation and results, from SEC filings.

TMO

Thermo Fisher Scientific Inc

$691.33

Value $257B

-1.27%
TMO's page

Royalty Pharma (RPRX) has a market value of $29.5B and Thermo Fisher Scientific (TMO) $257B. Over the last year, with dividends, RPRX moved +78.0% and TMO +19.9%. The P/E is 43.8 for RPRX and 36.3 for TMO. Dividend yield: RPRX 1.37%, TMO 0.27%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    RPRX$29.5B

    TMO$257B

    TMO is 8.7 times RPRX

  • Revenue, 12 months

    RPRX$2.6B

    TMO$47.4B

    TMO is 18 times RPRX

  • Net income, 12 months

    RPRX$672M

    TMO$7.1B

    TMO is 11 times RPRX

  • Operating margin

    RPRX57.1%

    TMO17.9%

    39.2 points apart

  • ROIC

    RPRX6.3%

    TMO8.2%

    1.9 points apart

  • P/E

    RPRX43.8

    TMO36.3

    RPRX is 1.2 times TMO

  • Dividend yield

    RPRX1.4%

    TMO0.3%

    1.1 points apart

  • 5-year return

    RPRX+85.3%

    TMO+10.9%

    74.4 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

RPRX+85.3%

TMO+10.9%

10015020222023202420252026
Returns by period
PeriodRPRXWith dividendsTMOWith dividends
1 year since November 14, 2025+78.0%Price +75.0%+19.9%Price +19.5%
3 years since November 16, 2023+177.6%+40.5% a yearPrice +158.3%+47.7%+13.9% a yearPrice +46.3%
5 years since November 15, 2021+85.3%+13.1% a yearPrice +64.3%+10.9%+2.1% a yearPrice +9.3%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

RPRXRoyalty PharmaTMOThermo Fisher Scientific

Valuation

RPRXTMO
Valuation
Price$68.53$691.33
Market value$29.5B$257B
Enterprise value (EV)$37.5B$292B
P/E43.836.3
P/E, 5-year median17.532.7
P/B3.04.7
EV/EBIT25.134.5
Free cash flow yield10.1%3.0%

Results and growth

RPRXTMO
Results and growth
Revenue, 12 months$2.6B$47.4B
Net income, 12 months$672M$7.1B
Free cash flow, 12 months$3.0B$7.6B
Earnings per share, 12 months$1.53$18.96
Revenue growth, year on year5.1%3.9%
Revenue growth a year, past+2.3%over 5 years+6.7%over 5 years
EPS growth a year, past+6.2%over 5 years+2.1%over 5 years

Margins and returns on capital

RPRXTMO
Margins and returns on capital
Gross margin––
Operating margin57.1%17.9%
Net margin25.7%14.9%
ROIC6.3%8.2%
ROE6.9%13.4%

Balance sheet

RPRXTMO
Balance sheet
Cash$545M$6.1B
Total debt$8.6B$41.4B
Net debt / EBITDA5.43.7
Interest cover4.0×5.5×

Dividends and buybacks

RPRXTMO
Dividends and buybacks
Dividend yield1.4%0.3%
Dividend per share, 12 months$0.94$1.84
Dividend growth a year, past–+14.3%over 5 years
Buyback yield4.2%1.2%
Shareholder yield5.5%1.4%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: RPRX or TMO

Didn't find what you were looking for?

Ask us
Which is bigger, Royalty Pharma or Thermo Fisher Scientific?

By market value, Thermo Fisher Scientific ($257B) is about 8.7 times Royalty Pharma ($29.5B), at today's prices.

How did RPRX and TMO stock do over the last 5 years?

Since November 15, 2021, RPRX's price moved +64.3% and TMO's +9.3%. With dividends: RPRX +85.3% (+13.1% a year), TMO +10.9% (+2.1% a year). Past returns do not predict future ones.

Which pays the higher dividend, RPRX or TMO?

The dividend yield at today's price is 1.37% for Royalty Pharma and 0.27% for Thermo Fisher Scientific. Over the last twelve months they paid $0.94 and $1.84 per share.

What is the P/E of RPRX and TMO?

At today's price, the P/E is 43.8 for RPRX and 36.3 for TMO. The median of the last five years was 17.5 and 32.7, which shows where each stands against its own past.

Which has the higher profit margins, Royalty Pharma or Thermo Fisher Scientific?

Over the last twelve months, the net margin was 25.7% for Royalty Pharma and 14.9% for Thermo Fisher Scientific, and the operating margin 57.1% and 17.9%. Revenue was $2.6B and $47.4B.

Which is the better investment, Royalty Pharma or Thermo Fisher Scientific?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.